Exhibit 99.1

Brainstorm Cell Therapeutics Nasdaq: BCLI

2 Safe Harbor Statement Statements in this announcement other than historical data and information constitute "forward-looking statements" and involve risks and uncertainties that could cause Brainstorm Cell Therapeutics Inc.'s actual results to differ materially from those stated or implied by such forward-looking statements. Terms and phrases such as "may", "should", "would", "could", "will", "expect", "likely", "believe", "plan", "estimate", "predict", "potential", and similar terms and phrases are intended to identify these forward-looking statements. The potential risks and uncertainties include, without limitation, risks associated with Brainstorm's limited operating history, history of losses; minimal working capital, dependence on its license to Ramot's technology; ability to adequately protect the technology; dependence on key executives and on its scientific consultants; ability to obtain required regulatory approvals; and other factors detailed in Brainstorm's annual report on Form 10-K and quarterly reports on Form 10-Q available at http://www.sec.gov. These factors should be considered carefully, and readers should not place undue reliance on Brainstorm's forward-looking statements. The forward-looking statements contained in this press release are based on the beliefs, expectations and opinions of management as of the date of this press release. We do not assume any obligation to update forward-looking statements to reflect actual results or assumptions if circumstances or management's beliefs, expectations or opinions should change, unless otherwise required by law. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, levels of activity, performance or achievements.

3 Brainstorm Cell Therapeutics: A Clinical Stage Biotechnology Company Our Mission Brainstorm pioneers autologous cell therapies for neurological disorders, focusing on ALS and MS Flagship Product NurOwn® - a cutting-edge autologous cell therapy platform Strong Pipeline NurOwn® innovative therapy serves as a platform for treating neurodegenerative diseases Experienced Leadership Decades of expertise in cell therapy and biopharma commercialization

4 Promising data from our previous trials continues to support the therapeutic potential of NurOwn®, demonstrating meaningful improvements in key areas. Robust biomarker data strongly supports NurOwn®’s mechanism of action. Aligned with FDA on new clinical trial design through the Special Protocol Assessment (SPA), ensuring regulatory confidence and trial integrity. Phase 3b plans: Comprehensive plan for Phase 3b trial, optimizing patient selection and dosing strategies. Pioneering Breakthrough: First-In-Class Therapy to Transform ALS Treatment

5 Indication Preclinical Phase 1 Phase 2 Phase 3 ALS* Progressive MS Parkinson's Disease ARDS NeurOwn® MSC-NTF Cellular Platform MSC-NTF Exosomes Platform Innovating Cell Therapies for Neurodegenerative Diseases *dependent on future funding Phase 3 Phase 3B

6 Experienced Team in Cell Therapy Development Proven Expertise Decades of experience in developing innovative cell therapies across multiple therapeutic areas. Successful Track Record Led the development of NurOwn®, producing over 470 GMP clinical batches for 190+ ALS trial. Extensive experience across all phases of clinical development, from preclinical to commercialization. Manufacturing Excellence Expertise in scaling up complex cell therapy manufacturing processes to meet clinical and regulatory standards. Regulatory and Quality Leadership Strong regulatory affairs team with a proven history of engaging with global health authorities, including the FDA and EMA. Innovation-Driven Approach Focus on cutting-edge science and advancing new cell therapy technologies to improve patient outcomes.

7 Chaim Lebovits President and CEO Bob Dagher, MD CMO Haro Hartounian, PhD COO Uri Yablonka CBO Mary Kay Turner SVP, Advocacy and Government Affairs Netta Blondheim-Sharga SVP, Research and Development Yossef Levy, PhD VP. Cell Production Leticia Tarilonte VP, Global Clinical Operations Proven Leadership with Deep Expertise in Biotechnology

8 Finalize agreements with leading clinical sites, setting the stage for a successful Phase 3b trial. Looking Ahead: Key Upcoming Expected Milestones Clinical Trial Agreements (CTA) Signed 15 Clinical Sites Announced Officially unveil our partnership with 15 premier clinical sites, ensuring broad geographic coverage and access to top-tier patient care. GMP Manufacturing in Full Swing GMP manufacturing of clinical-grade products is ready to support upcoming trials, ensuring timely execution and quality. Engaging Top-Tier CRO Signed an agreement with a leading CRO to manage patient recruitment, trial execution, and regulatory compliance, maximizing trial success. First Patient Enrollment by December On track to enroll the first patient in December 2024, marking a significant milestone in advancing NurOwn®.

Our Technology Cutting-Edge Innovation: Advancing the Future of Cell Therapy

10 Developing NurOwn® as a Groundbreaking Platform to Treat ALS • Survival is 2 to 5 years from onset, with a lifetime risk of 1 in 300 people. • ALS affects 1.6 per 100,000 people annually worldwide. • 90% to 95% of ALS cases are sporadic, with no known family history. • Projected to grow significantly, driven by factors such as advancements in research, rising prevalence due to aging populations, and emerging therapeutic modalities like cell and gene therapy. • Valued at approximately $669 million in 2023, is expected to surpass $1.2 billion by 2034, growing at a compound annual growth rate (CAGR) of around 6.4% (Datam Intelligence (IMARC). 1. Brotman RD, et al. StatPearls. 2020 2. Masrori P, et al. Eur J Neurol. 2020; 27:1918-1929 3. Brown RH, et al. N Engl J Med. 2017; 377:162-172 ALS is a progressive neurodegenerative disease that impairs walking, talking, eating, and breathing, and is currently 100% fatal

11 Amyotrophic Lateral Sclerosis- ALS Devastating Disease with Hope on the Horizon through Our Groundbreaking Treatment

12 Intrinsic immunomodulation properties Tropism to sites of damage In ALS murine models • Delay motor neuron degeneration • Improve motor performance • Prolong survival Multiple evidence for neuroprotection Deficient in several neurodegenerative diseases, including ALS Single NTFs tested as potential treatment in humans (e.g. BDNF & GDNF), with limited success MSCs NTFs MSC-NTFs (NurOwn®) Enhanced secretion of multiple NTF (e.g. VEGF, HGF, GDNF, BDNF & Gal-1) Enhanced immunomodulatory effects Enhanced effects in ALS and other neurodegenerative diseases NurOwn®: Harnessing MSC Characteristics and NTF Production

13 Our Technology: Transforming ALS Treatment with Advanced Cell Therapy NurOwn®: Uses the patient’s own cells, reducing immune rejection risks, contributes to the high tolerance and good safety profile, and enhancing natural neurorepair. Introduced to the spinal cord CSF, MSC-NTF cells secrete bioactive molecules like NTFs, microRNA, and cytokines, activating neuroprotective and immunomodulatory pathways after intrathecal administration. FDA-Approved Therapies: Riluzole and Edaravone offer limited benefits, targeting glutamate toxicity and oxidative stress, respectively. NurOwn® Platform: Explored for use in other neurodegenerative diseases like MS and Parkinson's, showing broad potential.

14 Changes in biomarkers across main-pathways following NurOwn treatment MCP-1 OPG S100B SDF-1a CHI3L1/YKL-40 Chitotriosidase-1 GFAP ICAM-1 IP-10* TREM-2 Inflammatory pathway Anti-Inflammatory pathway Fetuin-A IL-37 LAP (TGF-β1) MSR1 hsa-miR-146a-5p hsa-miR-146b-5p Neurodegeneration pathway pNfH DR6 NfL TWEAK Tau UCH-L1 hsa-miR-142-5p* Caspase-3 Neuroprotection pathway VEGF-A BDNF G-CSF GDF-15 Galectin-1 HGF NMNAT1 Clusterin/ ApoJ LIF Bold = significant change from baseline detected during the study; p<0.05 *= non-significant trend in other direction Robust biomarker data strongly supports NurOwn®’s mechanism of action

15 Change from placebo, neuroprotective markers Change from placebo, neurodegenerative and neuroinflammatory markers Illustrative approach to demonstrate the cumulative biomarker changes over time following NurOwn treatment, compared to placebo: Lindborg et al., 2024 Biomarkers Change Following NurOwn Treatment

16 Biomarkers in CSF from ALS patients demonstrate pathological hallmarks of active neurodegenerative and neuroinflammatory processes CSF biomarker changes following NurOwn treatment suggest a favorable disruption of pathological processes: • Reduction in CSF neuroinflammatory and neurodegenerative biomarkers • Increase observed in CSF anti-inflammatory and neuroprotective biomarkers NurOwn®: Tipping the Balance to Favor Neuroprotection Neuroinflammatory Neurodegeneration pathway Neuroprotective Anti-Inflammatory NurOwn® Treatment Neuroinflammatory Neurodegeneration pathway Neuroprotective Anti-Inflammatory

17 The NurOwn® Process: Step by Step The patient’s bone marrow is harvested and Mesenchymal Stromal Cells (MSCs) are isolated from the total bone marrow population. The MSCs are expanded ex-vivo and cryopreserved. Cryopreserved MSCs are thawed, expanded and induced to differentiate into MSC-NTF cells (MSC cells that secrete Neurotrophic Factors). The MSC-NTF cells are then injected back into the patient at or near the site of damage (the spinal cord).

18 Manufacturing Expertise: Delivering Quality and Scale for NurOwn® 470+ GMP Batches Produced: Proven ability to deliver clinical-grade materials at scale, dosing over 190 patients in multiple trials. Successfully executed technology transfer across multiple clinical sites for the production of NurOwn®, ensuring consistency and quality in manufacturing. State-of-the-Art Facilities: Advanced manufacturing in the US and Israel with cutting-edge technology for precision and efficiency. cGMP Compliance: Fully compliant with cGMP, ensuring consistent product quality and safety through rigorous quality controls. Global Manufacturing Footprint: Supporting global clinical and commercial needs with best-in-class facilities.

NurOwn® A Breakthrough in ALS Treatment with Promising Clinical Data

20 Phase 1/2 Phase 2a Phase 2 Phase 3 EAP Phase 3b N=12 N=14 N=48 N=189 N=10 N=200 Orphan Drug Designation Fast Track Designation FDA SPA Agreement Our Milestones: NurOwn® Development Program in ALS

21 Respiratory Function • Dyspnea • Orthopnea • Respiratory insufficiency Bulbar Function Gross Motor Function Fine Motor Function 48-point scale with 4 domains Primary Endpoint ALS Functional Rating Scale- Revised (ALSFRS-R) Validated approvable questionnaire-based tool Used as basis for approval of Radicava in 2017 with mean score change at 24 weeks as primary endpoint Data from the PRO-ACT database shows the average rate of ALSFRS-R decline is 1.02 points/month Change in ALSFRS-R slope (rate of disease progression) >20-25% is clinically meaningful2

22 NurOwn®: Phase 3 Clinical Trial in ALS (BCT-002-US) Subgroup analysis: positive results in early disease population (N=58) • Consistent treatment effects across multiple endpoints and over time • Over ~2 points benefit in function at Week 28 Pre-specified subgroup with baseline ALSFRS-R ≥35 • ALSFRS-R treatment difference nominally significant starting at week-12, through the end of trial NurOwn® Placebo * p ≤ 0.05 CFB in ALSFRS-R (95% CI)

23 NurOwn® demonstrated a significant treatment effect in subgroup of patient with less advanced disease. More advanced ALS patients did not show a treatment benefit, likely due to a floor effect. Data reinforces the safety of repeat intrathecal administration. The next trial will focus on enrolling less advanced patients and measuring the delta between the baseline and week 24 to maximize the statistical power. Clinical Data Summary

NurOwn®: Optimized Phase 3b Trial in Early ALS Disease

25 Part A: Double Blind Part B: Open Label NurOwn®: Phase 3 Clinical Trial in ALS (BCT-006-US) 9 weeks 24 Weeks 24 Weeks R NurOwn® Randomization Screening Placebo NurOwn® NurOwn® Intrathecal Injection every 8 weeks Upon successful completion of our double-blind Phase 3b study, we will be positioned to submit our Biologics License Application (BLA) for regulatory approval, potentially accelerating our path to market.

26 Phase 3 (BCT-002-US) Phase 3b (BCT-006) Patient population ≥25, followed by 20-week “run-in” period, allowing the possibility to enroll advanced-disease participants Early-disease participants: ALSFRS-R criteria targeting less advanced levels of functional decline (≥ 2 points on each item of the ALSFRS- R …) Primary endpoint Responder: proportion with ≥1.25 points/month improvement in the post-treatment slope vs. pre-treatment slope in ALSFRS-R at week 28 Use of “gold standard” in recent registrational trials (change from baseline to Week 24 in ALSFRS-R total score) • p-value derived from inference model of Combined Assessment of Function and Survival (CAFS) Study duration 28-week double blind period 24-week double blind (Part-A) to be followed by 24-week open label extension (Part B) • Extended to evaluate long-term effects on survival and neurodegenerative biomarkers Screening period 20 weeks screening, including 3-months “run-in” period to evaluate pre-treatment disease progression via ALSFRS-R Elimination of “run-in” and shortening of screening period to minimize changes between screening and baseline Regulatory Filing at week-28: Responder analysis in overall population, including advanced disease Filing at week-24: Special Protocol Assessment (SPA) agreement with FDA NurOwn® Phase 3b (BCT-006): Key Design Criteria Significant Changes Made to Upcoming Phase 3b Clinical Trial

27 NurOwn®: Positioned for Success Proven Expertise Our team has extensive experience in conducting clinical trials, including Phase 1, 2, and 3 studies. Regulatory Alignment Strong alignment from the FDA with Special Protocol Assessment (SPA) approval, ensuring trial design meets regulatory standards and de-risking regulatory aspects of the program. Data-Driven Approach Lessons from prior Phase 3 trials have refined patient selection, endpoints, and trial protocols, increasing the probability of success. Robust Manufacturing Process Securing partnerships with leading CDMOs for reliable production of clinical-grade materials, ensuring smooth execution. Operational Excellence A dedicated team, resources, and a clear execution plan are in place to manage and monitor the trial effectively.

28 Finalize agreements with leading clinical sites, setting the stage for a successful Phase 3b trial. Looking Ahead: Key Upcoming Expected Milestones Clinical Trial Agreements (CTA) Signed 15 Clinical Sites Announced Officially unveil our partnership with 15 premier clinical sites, ensuring broad geographic coverage and access to top-tier patient care. GMP Manufacturing in Full Swing GMP manufacturing of clinical-grade products is ready to support upcoming trials, ensuring timely execution and quality. Engaging Top-Tier CRO Signed an agreement with a leading CRO to manage patient recruitment, trial execution, and regulatory compliance, maximizing trial success. First Patient Enrollment by December On track to enroll the first patient in December 2024, marking a significant milestone in advancing NurOwn®.

Thank you Chaim Lebovits President & CEO BrainStorm Cell Therapeutics 1325 Avenue of Americas NY, NY 10019